<DOC>
	<DOCNO>NCT01593293</DOCNO>
	<brief_summary>The number NSCLC patient 70 year age non-squamous histology increase around world . Although previous guideline often recommend single agent therapy NSCLC , recent study suggest platinum doublet may better standard monotherapy elderly . We hypothesize elder patient ( ≥70 year age ) non-squamous NSCLC , pemetrexed carboplatin effective pemetrexed monotherapy term disease progression , overall survival , quality life tolerability .</brief_summary>
	<brief_title>Pemetrexed With Without Carboplatin Elderly Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The treatment NSCLC elderly subject discussion year . While platinum doublet consist cisplatin carboplatin another cytotoxic agent demonstrate survival advantage compare single agent generally , evidence treatment efficacy patient diminish performance status ( PS ) age old 70 year limited . Guidelines US Europe prefer single-agent chemotherapy elderly PS 2 patient . However , increase study explore issue present data favour doublet therapy . The addition carboplatin paclitaxel cisplatin docetaxel show evidence patient 70 benefit face increase toxicity . This study design multi-center , open-label , prospective , randomize , two-arm , parallel , phase III trial elderly patient ( ≥70 year old ) metastatic non-squamous NSCLC ( Stage IV AJCC 7th ) receive prior systemic chemotherapy biological therapy . Approximately 266 patient enrolled trial . This study compare doublet therapy pemetrexed ( 500 mg/m2 ) carboplatin ( AUC 5 mg/mL*min ) administer intravenously every 21 day 4 cycle follow pemetrexed ( 500 mg/m2 ) every 21 day maintenance therapy ( Arm A ) single therapy pemetrexed ( 500 mg/m2 ) every 21 day till progression unacceptable toxicity ( Arm B ) . Pemetrexed administer vitamin B12 folate supplement .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm advanced nonsquamous nonsmall cell lung cancer ( stage IV , AJCC 7th ) Age 70 year old old Eastern Cooperative Oncology Group performance status 01 Measurable assessable disease define RECIST 1.1 Estimated life expectancy 3 month Adequate bone marrow function ( Absolute Neutrophil Count ( ANC ) ≥ 1,500/µL , platelet ≥ 100,000/µL , hemoglobulin ≥ 9 g/dL ) Adequate renal function : creatinine &lt; 1 x upper normal limit ( UNL ) creatinine clearance ( Ccr ) use Cockroft Gault formula ≥45 ml/min Adequate hepatic function : bilirubin &lt; 1.5 x UNL , AST/ALT level &lt; 3 x UNL , alkaline phosphatase &lt; 3 x UNL ( except case bone metastasis without liver disease ) Written informed consent Prior systemic chemotherapy biological therapy Contraindication drug contain chemotherapy regimen Clinically significant thirdspace fluid collection ( e.g . pleural effusion pericardial effusion ) control drainage procedure prior study enrollment Active infection would compromise patient 's ability tolerate treatment Requirement major surgery within 4 week study entry Myocardial infarction , uncontrolled arrhythmia , symptomatic angina pectoris , cardiac failure within previous 6 month Unable discontinue administration aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) ; Aspirin NSAIDs least 5 day pemetrexed administration Presence history CNS metastasis ( except adequately treat receive steroid therapy least 2 week ; least 2 week whole brain radiation least 1 week gamma knife surgery ) Peripheral neuropathy ≥ grade 2 History another malignancy within last five year except cure basal cell carcinoma skin , cure carcinoma insitu uterine cervix cure thyroid malignancy Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Elderly patient</keyword>
	<keyword>Non-squamous Non-small Cell Lung Cancer</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Carboplatin</keyword>
</DOC>